Practical considerations when treating chronic hepatitis E in solid organ transplant recipients.


Journal

International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 23 06 2020
accepted: 03 11 2020
revised: 31 10 2020
pubmed: 11 11 2020
medline: 16 10 2021
entrez: 10 11 2020
Statut: ppublish

Résumé

Hepatitis E virus (HEV) can lead to chronic infections in immunosuppressed patients. The use of ribavirin to treat chronic HEV has been well-established in case reports and guidelines. However, practical approaches to the use of this antiviral treatment in a post-transplant patient, including drug interactions, dosing adjustments, and monitoring parameters, are lacking. Thus, we present our real-world approach to the use of ribavirin to treat chronic HEV in a solid organ transplant recipient.

Identifiants

pubmed: 33169803
doi: 10.1007/s11096-020-01195-x
pii: 10.1007/s11096-020-01195-x
doi:

Substances chimiques

Antiviral Agents 0
Ribavirin 49717AWG6K

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

753-755

Références

Hepatitis E. World Health Organization. 2020. https://www.who.int/news-room/fact-sheets/detail/hepatitis-e . Accessed 1 Oct 2020.
Hepatitis E. Centers for Disease Control and Prevention. 2020. https://www.cdc.gov/hepatitis/hev/index.htm . Accessed 1 Oct 2020.
European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256–71.
doi: 10.1016/j.jhep.2018.03.005
Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370(12):1111–20.
doi: 10.1056/NEJMoa1215246
Colson P, Decoster C. Recent data on hepatitis E. Curr Opin Infect Dis. 2019;32(5):475–81.
doi: 10.1097/QCO.0000000000000590

Auteurs

David K Choi (DK)

University of Illinois at Chicago College of Pharmacy, 833 S Wood Street, Suite 164, M/C 886, Chicago, IL, 60612, USA. Dchoi90@uic.edu.

Michelle T Martin (MT)

University of Illinois at Chicago College of Pharmacy, 833 S Wood Street, Suite 164, M/C 886, Chicago, IL, 60612, USA.

Wadih Chacra (W)

Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL, USA.

Christine Chan (C)

Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL, USA.

Sean Koppe (S)

Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL, USA.

Lisa Landers (L)

Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL, USA.

Ammara Naveed (A)

Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL, USA.

Adam E Mikolajczyk (AE)

Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, IL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH